Vagus Nerve Stimulation As Treatment for Epileptic Seizures

Abstract

Vagus nerve stimulation is a unique therapy for epileptic seizures. Two randomized controlled trials in patients with medically refractory partial seizures have demonstrated efficacy, leading to US Food and Drug Administration approval of vagus nerve stimulation therapy in 1997. Extensive safety testing has not revealed significant effects on cardiac, respiratory, or gastrointestinal function, though recent reports of intraoperative asystole and sleep-related airway obstruction have raised concerns. Vagus nerve stimulation is indicated for adjunctive therapy of partial-onset seizures in children and individuals older than 12 years (Class I evidence). Based on controlled, randomized trials, approximately 30% of these patients can be expected to have at least a 50% decrease in overall seizure frequency. Vagus nerve stimulation efficacy is similar to that of several newer antiepileptic drugs when used in similar populations in controlled, randomized trials. Long-term follow-up studies suggest continued efficacy over more than 1 year (Class III evidence). Case series suggest similar or greater efficacy in younger children, and in patients with refractory generalized seizures, including those associated with the Lennox-Gastaut syndrome (Class III evidence). Vagus nerve stimulation is appropriate therapy for patients with medically refractory epileptic seizures who are not optimal candidates for resective epilepsy surgery.